Publications by authors named "Leonie Bluhm"
Article Synopsis
- This study focused on advanced melanoma patients who developed brain metastases and how their treatment type influenced these outcomes.
- A total of 1,704 patients were analyzed, showing that those treated with BRAF+MEK therapy had a higher incidence of brain metastases compared to those receiving PD-1 therapies after 24 months.
- Findings indicated that the type of first-line therapy, along with tumor stage and patient age, were important factors affecting brain metastasis-free survival and overall survival in BRAF-positive melanoma patients.
Article Synopsis
- This study examines the challenges of treating melanoma brain metastasis (MBM) and the effects of various therapies on patient survival outcomes, utilizing data from 450 patients in a skin cancer registry.
- Key findings indicate that radiotherapy significantly improves overall survival, while the type of initial therapy (immune checkpoint blockade or targeted therapy) does not show independent prognostic value.
- Second-line BRAF+MEK targeted therapy demonstrated better survival compared to other treatments, especially when used after immune checkpoint blockade.
Background: Elevated lactate dehydrogenase (LDH) is a known predictive and prognostic factor for a poor outcome in patients with metastatic melanoma. It is unclear whether first-line targeted therapy (TT) or immune checkpoint inhibition (ICI) is more beneficial in melanoma patients with elevated LDH because prospective studies in this area are lacking.
Methods: This multicentre retrospective cohort study was conducted at 25 melanoma centres worldwide to analyse progression-free survival (PFS) and overall survival (OS) among melanoma patients with elevated LDH.
The combination of liquid biomarkers from a single blood tube can provide more comprehensive information on tumor development and progression in cancer patients compared to single analysis. Here, we evaluated whether a combined analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and circulating cell-free microRNA (miRNA) in total plasma and extracellular vesicles (EV) from the same blood sample is feasible and how the results are influenced by the choice of different blood tubes. Peripheral blood from 20 stage IV melanoma patients and five healthy donors (HD) was collected in EDTA, Streck, and Transfix tubes.
View Article and Find Full Text PDFPurpose: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were excluded in these studies, the Dermatologic Cooperative Oncology Group (DeCOG) conducted a phase II to assess the efficacy and safety of ipilimumab in patients with metastatic UM.
View Article and Find Full Text PDF